2 Comments
User's avatar
Dr. Shobhita Gupta's avatar

Brilliant take. The bottleneck is no longer discovery/knowledge, it’s manufacturing, and AI hasn’t touched that yet. That asymmetry is going to be a defining tension, and I don’t think biopharma is remotely prepared for it.

Andrii Buvailo, PhD's avatar

Thank you. Eli Lilly's CIO recently said that they actually increased production of GLP-1 owing to AI in manufacturing, things like capacity planning, equipment monitoring etc... they built digital twins of their manufacturing process. However, it is still not solving the key problem: it is still a physical world, and you need to "move atoms" and not just information.